Skip to main content

Table 6 Adverse events reported during the study (N = 78)

From: Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study

Adverse event

Cases

Withdrawals

Treatment at the time of withdrawal*

Vitreous hemorrhage

1

0

 

Pruritus

1

0

 

Severe hyperemia

3

3

bim/tim (2), dorz/brim/tim (1)

Sensation of foreign body and conjunctival edema

1

1

bim/tim

Severe eyelid edema

1

0

 

Reduced visual field

1

1

dorz/brim/tim

Allergy

1

0

 

Significantly reduced vision

1

0

 

Blurred vision

1

0

 

Not specified

1

1

dorz/brim/tim

Total

12

6

 
  1. *Refers to the study medication taken at the time of withdrawal, but does not indicate that the adverse event was treatment-related.
  2. Nonparametric chi-square test, P = 0.202.
  3. Bim/tim, bimatoprost 0.03% and timolol maleate 0.5%; dorz/brim/tim, dorzolamide 2%, brimonidine 0.2%, and timolol maleate 0.5%.